PRC
MYGN icon

Platte River Capital’s Myriad Genetics MYGN Stock Holding History

Platte River Capital’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-47,280
Closed -$1.27M – 217
2013
Q2 		$1.27M Buy
+47,280
New +$1.37M 0.15% 142

Other funds holding MYGN

RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
BTS
BB&T Securities Richmond, Virginia $10.9B AUM 5.31% 1-Year Est. Return
MNA
Manning & Napier Advisors Fairport, New York $7.09B AUM 17.35% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
MCM
Munder Capital Management Birmingham, Michigan $13.4B AUM 18.35% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SCM
Sterling Capital Management Charlotte, North Carolina $5.28B AUM 23.15% 1-Year Est. Return
SFM
Systematic Financial Management Teaneck, New Jersey $4.36B AUM 40.56% 1-Year Est. Return

Platte River Capital's MYGN Position: Q3 2013 in Review

Platte River Capital sold out of Myriad Genetics (MYGN) in Q3 2013, closing a stake of 47,280 shares — an estimated $1.27M sold.

Platte River Capital first reported a position in MYGN in Q2 2013 and held it in 1 quarter. The position peaked at $1.27M in Q2 2013. 267 funds tracked by Wall St. Rank hold MYGN as of Q3 2013.

  • Platte River Capital reported no remaining Myriad Genetics position as of Q3 2013 after selling out during the quarter.
  • Platte River Capital sold 47,280 Myriad Genetics shares in Q3 2013, an estimated $1.27M.
  • Platte River Capital first reported a position in Myriad Genetics in Q2 2013 and held it in 1 quarter.
  • Platte River Capital's Myriad Genetics position peaked at $1.27M in Q2 2013.
  • 267 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2013.

Based on Platte River Capital's 13F filing for Q3 2013, filed 8 Nov 2013.